Department of Radiation Oncology, Dana Farber Cancer Institute, Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02215, USA.
Int J Mol Sci. 2023 Jan 4;24(2):923. doi: 10.3390/ijms24020923.
Low-level tumor somatic DNA mutations in tissue and liquid biopsies obtained from cancer patients can have profound implications for development of metastasis, prognosis, choice of treatment, follow-up, or early cancer detection. Unless detected, such low-frequency DNA alterations can misinform patient management decisions or become missed opportunities for personalized medicine. Next-generation sequencing technologies and digital-PCR can resolve low-level mutations but require access to specialized instrumentation, time, and resources. Enzymatic-based approaches to detection of low-level mutations provide a simple, straightforward, and affordable alternative to enrich and detect such alterations and is broadly available to low-resource laboratory settings. This review summarizes the traditional uses of enzymatic mutation detection and describes the latest exciting developments, potential, and applications with specific reference to the field of liquid biopsy in cancer.
从癌症患者的组织和液体活检样本中检测到低水平的肿瘤体细胞 DNA 突变,可能对转移、预后、治疗选择、随访或早期癌症检测产生深远影响。如果不进行检测,这些低频率的 DNA 改变可能会误导患者管理决策,或错失个性化医疗的机会。下一代测序技术和数字 PCR 可以解决低水平突变问题,但需要使用专门的仪器、时间和资源。基于酶的检测低水平突变的方法提供了一种简单、直接且经济实惠的替代方法来富集和检测这些改变,并且广泛适用于资源有限的实验室环境。本综述总结了酶突变检测的传统用途,并描述了最新的令人兴奋的发展、潜力和应用,特别参考了癌症液体活检领域。